Phase I trials: Role of the nurse investigator

  • Teresa J. Melink
Part of the Cancer Treatment and Research book series (CTAR, volume 42)

Abstract

The development of new anticancer therapy remains an essential strategy in our efforts against cancer. While notable advances in the treatment of certain malignancies have been achieved [1–5], many are still without successful therapies. The clinical trial serves as a mechanism whereby new and previously existing treatment modalities are evaluated in humans [6]. Such trials proceed in an orderly process following preclinical evaluation of antitumor activity and toxicologic and pharmacologic determinations [7]. The three phases and objectives of clinical drug development include:
  • Phase I studies To determine the safest maximum tolerated dose and establish a dose that can be used for phase II trials. To define qualitative and quantitative toxicities of a new compound on a given schedule. To evaluate the basic clinical pharmacology of the drug.

  • Phase II studies To identify the therapeutic efficacy of a new treatment in a variety of tumor types with specific regard to objective response rates and duration.

  • Phase III studies To determine the effects of a new treatment on the natural history of the disease. To discover whether a new treatment is more effective than standard therapy and whether it is associated with less morbidity.

Keywords

Lymphoma Oncol Interferon Dexamethasone Proteinuria 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bonadonna G, Rossi A, Valagussa P, et al.: The CMF program for operable breast cancer with positive axillary nodes. Cancer 39:2904–2915, 1977.PubMedCrossRefGoogle Scholar
  2. 2.
    De Vita VT, Serpick AA, and Carbone PP: Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73:891–895, 1970.Google Scholar
  3. 3.
    De Vita VT, Canellos GP, Chabner BA, et al.: Advanced diffuse histiocytic lymphoma, a potentially curable disease: results with combination chemotherapy. Lancet 1:248–250, 1975.Google Scholar
  4. 4.
    Weinstein HJ, Mayer RJ, Rosenthal DS, et al.: Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 303:473, 1980.PubMedCrossRefGoogle Scholar
  5. 5.
    Einhorn LH and Donohue JP: Cisdiamminedichloroplatinum, vinblastine and bleomycin combination in disseminated testicular cancer. Ann Intern Med 87:293–298, 1977.PubMedGoogle Scholar
  6. 6.
    Gehan EA: Planning clinical trials. Cancer Bull 32:200–206, 1980.Google Scholar
  7. 7.
    Woolley PV and Schein PS: Clinical pharmacology and phase I trial design. Methods Cancer Res 17:177–198, 1979.Google Scholar
  8. 8.
    Von Hoff DD, Kuhn J, and Clark GM: Design and conduct of phase I trials. In: Cancer clinical trials: methods and practice, ME Buyse, MJ Staquet, and RJ Sylvester (eds). Oxford: Oxford University, pp 210–220, 1984.Google Scholar
  9. 9.
    Henke C: Emerging roles of the nurse in oncology. Semin Oncol 7:4–8, 1980.PubMedGoogle Scholar
  10. 10.
    Hubbard SM and Donehower MG: The nurse in a cancer research setting. Semin Oncol 7:9–17, 1980.PubMedGoogle Scholar
  11. 11.
    Hubbard S and De Vita V: Chemotherapy research nurse. Am J Nurs 76:560–565, 1976.PubMedGoogle Scholar
  12. 12.
    Hubbard SM: Cancer treatment research: the role of the nurse in clinical trials of cancer therapy. Nurs Clin North Am 17:763–783, 1982.PubMedGoogle Scholar
  13. 13.
    Gross J: Clinical research in cancer chemotherapy. Oncol Nurs Forum 13:59–64, 1986.PubMedGoogle Scholar
  14. 14.
    Melink TJ, Von Hoff DD, Kuhn JG, et al.: Phase I evaluation and pharmacokinetics of tiazofurin (NSC 286193). Cancer Res 45:2859–2865, 1985.PubMedGoogle Scholar
  15. 15.
    Neidhart JA, Gage MM, Young D, et al.: Interferon therapy of renal cancer. Cancer Res 44:4140–4143, 1984.PubMedGoogle Scholar
  16. 16.
    Hubbard SP, Chabner BA, Canellos GP, et al.: High dose intravenous bleomycin in the treatment of advanced lymphomas. Eur J Cancer 11:623–626, 1975.PubMedCrossRefGoogle Scholar
  17. 17.
    Coltman CA Jr, McDaniel TM, Balcerzak S, et al.: Mitoxantrone hydrochloride (NSC 301739) in lymphoma, a Southwest Oncology Group study. Invest New Drugs 1:65–70, 1983.PubMedCrossRefGoogle Scholar
  18. 18.
    Coons HL, Leventhal H, Nerenz DR, et al.: Anticipatory nausea and emotional distress in patients receiving cisplatin-based chemotherapy. Oncol Nurs Forum 14:31–35, 1987.PubMedGoogle Scholar
  19. 19.
    Strohl RA and Salazar OM: Management of the patient receiving hemibody irradiation. Oncol Nurs Forum 9:13–16, 1982.PubMedGoogle Scholar
  20. 20.
    Wood HA and Ellerhorst-Ryan JM: Delayed adverse skin reactions associated with mito-mycin-C administration. Oncol Nurs Forum 11:14–18, 1984.PubMedGoogle Scholar
  21. 21.
    Kennedy M, Packard R, Grant M, et al.: The effects of using Chemocap on occurrence of chemotherapy-induced alopecia. Oncol Nurs Forum 10:19–23, 1983.PubMedGoogle Scholar
  22. 22.
    Kane KK: Carotid artery rupture in advanced head and neck cancer patients. Oncol Nurs Forum 10:14–18, 1983.PubMedGoogle Scholar
  23. 23.
    Guthercole F, Connolly N, and Budsel J: The use of dexamethasone (Hexadrol) as an antiemetic in association with chemotherapy for neoplastic disease. Oncol Nurs Forum 9:17–19, 1982.Google Scholar
  24. 24.
    Dangel BB: Pruritus and cancer. Oncol Nurs Forum 13:17–21, 1986.PubMedGoogle Scholar
  25. 25.
    Durgon A: Anticipatory nausea and vomiting associated with cancer chemotherapy. Oncol Nurs Forum 13:35–40, 1986.Google Scholar
  26. 26.
    Carter SK: Clinical trials in cancer chemotherapy. Cancer 40:544–557Google Scholar
  27. 27.
    Investigators handbook. Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, Nov 1986.Google Scholar
  28. 28.
    Freireich EJ, Gehan EA, Rall DP, Schmidt LH, and Skipper HE: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Res 50:219–244, 1966.Google Scholar
  29. 29.
    Sylvester R: Planning cancer clinical trials. In: Cancer clinical trials: methods and practice, ME Buyse, MJ Staquet, and RJ Sylvester (eds). Oxford: Oxford University, pp 47–55, 1984.Google Scholar
  30. 30.
    Scogna DM: Nursing research in a cancer cooperative group setting. Cancer Nurs 4:277–280, 1981.PubMedCrossRefGoogle Scholar
  31. 31.
    Lipsett MB: On the nature and ethics of phase I clinical trials of cancer chemotherapies. JAMA 248:941–942, 1982.PubMedCrossRefGoogle Scholar
  32. 32.
    Taub S: Cancer and the law of informed consent. Law Med Health Care:61–66, 1982.Google Scholar
  33. 33.
    Herbert V: Informed consent: a legal evaluation. Cancer 46:1042–1044, 1980.CrossRefGoogle Scholar
  34. 34.
    Markman M: The ethical dilemma of phase I clinical trials. CA 36:367–369, 1986.PubMedGoogle Scholar
  35. 35.
    US Code of Federal Regulations, Title 45 CFR 46, Public Welfare Final Regulations Amending Basic HHS Policy for the Protection of Research Subjects. Fed Reg 4:8366–8392, 1981.Google Scholar
  36. 36.
    Mullen SM, Warwick S, Akers M, et al.: An acute intervention trial: the research nurse coordinator’s role. Control Clin Trials 5:141–156, 1984.CrossRefGoogle Scholar
  37. 37.
    Raymond V: The oncology nurse as clinical trials coordinator. In: Oncology Nurses Society 9th annual Congress, Toronto, Canada, 1984.Google Scholar
  38. 38.
    Jeffs C and Laszlo J: A coordinating role for the nurse clinican in a phase I interferon study. Cancer Nurs 6:379–386, 1983.PubMedCrossRefGoogle Scholar
  39. 39.
    Rinker M and Stewart JA: The role of oncology nurses in phase I trials in a rural environment. In: Oncology Nurses Society 8th annual Congress, San Diego, California, 1983.Google Scholar
  40. 40.
    Frank-Stromberg M, Wright PS, Segalla M, and Diekmann J: Psychological impact of the “cancer” diagnosis. Oncol Nurs Forum 11:16–22, 1984.Google Scholar
  41. 41.
    Grant MM and Padilla GV: An overview of cancer nursing research. Oncol Nurs Forum 10:58–69, 1983.PubMedGoogle Scholar
  42. 42.
    National Study Commission on Cytotoxic Exposure: Recommendations for handling cytotoxic agents. Mar 1984.Google Scholar
  43. 43.
    Le Roy ML, Roberts MJ, and Theisen JA: Procedures for handling antineoplastic injections in comprehensive cancer centers. Am J Hosp Pharm 40:601–603, 1983.Google Scholar
  44. 44.
    Stolar MH, Power LA, and Viele CS: Recommendations for handling cytotoxic drugs in hospitals. Am J Hosp Pharm 40:1163–1171, 1983.PubMedGoogle Scholar
  45. 45.
    Zimmerman PF, Larsen RK, Barkley EW, and Gallelli JF: Recommendations for the safe handling of injectable antineoplastic drug products. Am J Hosp Pharm 38:1693–1695, 1981.PubMedGoogle Scholar
  46. 46.
    Gross J, Johnson BL, and Bertino JR: Possible hazards of working with cytotoxic agents. Oncol Nurs Forum 8:10–12, 1981.PubMedGoogle Scholar
  47. 47.
    Kisner DL: Reporting treatment toxicities. In: Cancer clinical trials: methods and practice, ME Buyse, MJ Staquet, and RJ Sylvester (eds). Oxford: Oxford University, pp 178–190, 1984.Google Scholar
  48. 48.
    Vietti TJ: Evaluation of toxicity: clinical issues. Cancer Treat Rep 64:457–461, 1980.PubMedGoogle Scholar
  49. 49.
    Ryan LS, Edwards RL, and Rickles FR: A joint practice approach to the care of persons with cancer. Oncol Nurs Forum 7:8–11, 1980.PubMedGoogle Scholar
  50. 50.
    Maxwell MB: Nurse practitioner chemotherapy clinic. Cancer Nurs 2:211–218, 1979.PubMedCrossRefGoogle Scholar
  51. 51.
    Antonelli DM: Data management and the cancer treatment protocol. Cancer Nurs 5:447–479, 1982.Google Scholar
  52. 52.
    Melink TJ, Von Hoff DD, Clark GM, and Coltman CA: Impact of phase I clinical trials on the quality of life and survival of cancer patients [abstr]. Proc Am Soc Clin Oncol 4:251, 1985.Google Scholar
  53. 53.
    Strauman JJ: Symptom distress in patients receiving phase I chemotherapy with Taxol. Oncol Nurs Forum 13:40–43, 1986.PubMedGoogle Scholar
  54. 54.
    Hersh MR, Linn W, Kuhn JG, and Von Hoff DD: Electrocardiographic monitoring of patients receiving phase I chemotherapy. Cancer Treat Rep 70:349–352, 1986.PubMedGoogle Scholar
  55. 55.
    Brown T, Boyd J, Clark G, et al.: Concomitant medications during phase I trials [abstr]. Proc Am Soc Clin Oncol 4:39, 1985.Google Scholar
  56. 56.
    Benoliel JQ: The historical development of cancer nursing research in the United States. Cancer Nurs 6:261–268, 1983.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • Teresa J. Melink

There are no affiliations available

Personalised recommendations